Current landscape of miRNAs and TGF‐β signaling in lung cancer progression and therapeutic targets

IF 2.3 3区 生物学 Q3 BIOCHEMICAL RESEARCH METHODS
Bashdar Mahmud Hussen , Safeen Jasim Saleem , Snur Rasool Abdullah , Sayran Mohamadtahr , Hazha Jamal Hidayat , Mohammed Fatih Rasul , Mohammad Taheri , Arda Kiani
{"title":"Current landscape of miRNAs and TGF‐β signaling in lung cancer progression and therapeutic targets","authors":"Bashdar Mahmud Hussen ,&nbsp;Safeen Jasim Saleem ,&nbsp;Snur Rasool Abdullah ,&nbsp;Sayran Mohamadtahr ,&nbsp;Hazha Jamal Hidayat ,&nbsp;Mohammed Fatih Rasul ,&nbsp;Mohammad Taheri ,&nbsp;Arda Kiani","doi":"10.1016/j.mcp.2023.101929","DOIUrl":null,"url":null,"abstract":"<div><p>Lung cancer (LC) is the primary reason for cancer-associated fatalities globally. Due to both tumor-suppressing and tumor-promoting activities, the TGF-β family of growth factors is extremely essential to tumorigenesis. A non-coding single-stranded short RNA called microRNA (miRNA), which is made up of about 22 nt and is encoded by endogenous genes, can control normal and pathological pathways in various kinds of cancer, including LC. Recent research demonstrated that the TGF-β signaling directly can affect the synthesis of miRNAs through suppressor of mothers against decapentaplegic (SMAD)-dependent activity or other unidentified pathways, which could generate allostatic feedback as a result of TGF-β signaling stimulation and ultimately affect the destiny of cancer tissues. In this review, we emphasize the critical functions of miRNAs in lung cancer progression and, more critically, how they affect the TGF-β signaling pathway, and explore the role of both the TGF-β signaling pathway and miRNAs as potential therapeutic targets for improving the treatments of LC patients.</p></div>","PeriodicalId":49799,"journal":{"name":"Molecular and Cellular Probes","volume":"72 ","pages":"Article 101929"},"PeriodicalIF":2.3000,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and Cellular Probes","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0890850823000385","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

Lung cancer (LC) is the primary reason for cancer-associated fatalities globally. Due to both tumor-suppressing and tumor-promoting activities, the TGF-β family of growth factors is extremely essential to tumorigenesis. A non-coding single-stranded short RNA called microRNA (miRNA), which is made up of about 22 nt and is encoded by endogenous genes, can control normal and pathological pathways in various kinds of cancer, including LC. Recent research demonstrated that the TGF-β signaling directly can affect the synthesis of miRNAs through suppressor of mothers against decapentaplegic (SMAD)-dependent activity or other unidentified pathways, which could generate allostatic feedback as a result of TGF-β signaling stimulation and ultimately affect the destiny of cancer tissues. In this review, we emphasize the critical functions of miRNAs in lung cancer progression and, more critically, how they affect the TGF-β signaling pathway, and explore the role of both the TGF-β signaling pathway and miRNAs as potential therapeutic targets for improving the treatments of LC patients.

miRNAs和TGF-β信号在癌症进展和治疗靶点中的现状
癌症(LC)是全球癌症相关死亡的主要原因。由于具有肿瘤抑制和肿瘤促进活性,TGF-β生长因子家族对肿瘤的发生至关重要。一种称为微小RNA(miRNA)的非编码单链短RNA,由约22nt组成,由内源性基因编码,可以控制包括LC在内的各种癌症的正常和病理途径。最近的研究表明,TGF-β信号可直接影响miRNA的合成,通过抑制母亲对半身不遂(SMAD)依赖性活动的抑制或其他未确定的途径,这些途径可作为TGF-β的信号刺激的结果产生异位反馈,并最终影响癌症组织的命运。在这篇综述中,我们强调了miRNA在癌症进展中的关键功能,更重要的是,它们如何影响TGF-β信号通路,并探讨了TGF-β信令通路和miRNA作为改善LC患者治疗的潜在治疗靶点的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular and Cellular Probes
Molecular and Cellular Probes 生物-生化研究方法
CiteScore
6.80
自引率
0.00%
发文量
52
审稿时长
16 days
期刊介绍: MCP - Advancing biology through–omics and bioinformatic technologies wants to capture outcomes from the current revolution in molecular technologies and sciences. The journal has broadened its scope and embraces any high quality research papers, reviews and opinions in areas including, but not limited to, molecular biology, cell biology, biochemistry, immunology, physiology, epidemiology, ecology, virology, microbiology, parasitology, genetics, evolutionary biology, genomics (including metagenomics), bioinformatics, proteomics, metabolomics, glycomics, and lipidomics. Submissions with a technology-driven focus on understanding normal biological or disease processes as well as conceptual advances and paradigm shifts are particularly encouraged. The Editors welcome fundamental or applied research areas; pre-submission enquiries about advanced draft manuscripts are welcomed. Top quality research and manuscripts will be fast-tracked.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信